Krensavage Asset Management, LLC
Registered adviserRegulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
| Rosters | Regulatory AUM | Main clients |
|---|---|---|
| Apr 2026 to Oct 2026 | $300,227,111 | Pooled investment vehicles (100%) |
| Dec 2025 to Mar 2026 | $203,270,643 | Pooled investment vehicles (100%) |
| Apr 2025 to Sep 2025 | $203,270,643 | Pooled investment vehicles (100%) |
| Apr 2024 to Mar 2025 | $310,705,033 | Pooled investment vehicles (100%) |
| May 2023 to Mar 2024 | $376,884,624 | Pooled investment vehicles (100%) |
| Apr 2023 | $376,884,624 | Pooled investment vehicles (100%) |
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the S&P MidCap 400 as of 2026-06-30, active share 98.3%; sector active share 90.6% against the combined 13F book's sector weights.
Over time 26 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
18 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $263,224,522 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increasedNew Positions
Positions the filer opened this quarter| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| ENTA |
Enanta Pharmaceuticals Inc
Healthcare
|
Held | 2,866,138 | $41,788,292 | 15.88% | |
| JAZZ |
Jazz Pharmaceuticals plc
Healthcare
|
Held | 167,816 | $40,438,621 | 15.36% | |
| UTHR |
UNITED THERAPEUTICS Corp
Healthcare
|
Reduced | 69,282 | $37,539,066 | 14.26% | |
| BMRN |
Biomarin Pharmaceutical Inc
Healthcare
|
Held | 524,786 | $30,028,254 | 11.41% | |
| EXEL |
Exelixis, Inc.
Healthcare
|
Reduced | 370,693 | $20,169,406 | 7.66% | |
| ABT |
Abbott Laboratories
Healthcare
|
Added | 200,000 | $18,148,000 | 6.89% | |
| SNY |
Sanofi
Healthcare
|
Held | 323,946 | $13,819,536 | 5.25% | |
| SUPN |
Supernus Pharmaceuticals, Inc.
Healthcare
|
Held | 280,681 | $13,054,473 | 4.96% | |
| RARE |
Ultragenyx Pharmaceutical Inc.
Healthcare
|
Held | 390,879 | $13,051,449 | 4.96% | |
| VNDA |
Vanda Pharmaceuticals Inc.
Healthcare
|
Held | 1,180,388 | $7,223,974 | 2.74% | |
| BNTX |
BioNTech SE
Healthcare
|
Held | 59,523 | $5,538,615 | 2.10% | |
| GSK |
GSK plc
Healthcare
|
Held | 96,729 | $5,070,534 | 1.93% | |
| BIIB |
Biogen Inc.
Healthcare
|
Held | 20,000 | $4,321,200 | 1.64% | |
| REGN |
Regeneron Pharmaceuticals, Inc.
Healthcare
|
Added | 6,000 | $3,741,240 | 1.42% | |
| EMBC |
Embecta Corp.
Healthcare
|
Added | 1,135,340 | $3,701,208 | 1.41% | |
| ARDX |
Ardelyx, Inc.
Healthcare
|
Added | 534,523 | $2,726,067 | 1.04% | |
| INMD |
InMode Ltd.
Healthcare
|
Held | 120,942 | $1,768,172 | 0.67% | |
| EOLS |
Evolus, Inc.
Healthcare
|
Held | 157,985 | $1,096,415 | 0.42% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.